KIT Gene Mutations in Gastrointestinal Stromal Tumors
Jonathan A. Fletcher(Harvard University), Michael C. Heinrich(VA Portland Health Care System), Brian P. Rubin(Cleveland Clinic), Christopher L. Corless(Oregon Health & Science University), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Leonie K. Ashman(Hunter Medical Research Institute)
Cited by 25
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases
|International Journal of Cancer|2006|680
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647